4th Hospital is Now Equipped with Quantum Surgical’s Minimally Invasive Surgical Robot That Kills Tumors

Minimally Invasive Surgical Robot

The Paoli-Calmettes Insitute (IPC) acquired Epione®, Quantum Surgical’ robotic platform which enables curative and early treatment of tumors. The first patient was treated yesterday in Marseille. The IPC is the 4th center in the world to offer its patients this minimally invasive treatment in which one or several needles are inserted through the skin into the tumor to destroy it.

Epione®

Epione® is a robot-assisted technology that enables interventional radiologists to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment where one or more needles are inserted through the skin to destroy the tumor. This platform is designed to plan, target, execute, and confirm the ablation of abdominal and pulmonary tumors, with other locations currently under study.

After Baptist Health Hospital in Miami, Gustave Roussy Institute in Villejuif, and Hospices Civils de Lyon, the Paoli-Calmettes Institute is the fourth center in the world to acquire the Epione® robot.

Patient Benefits

For over 10 years, at IPC, patients have been benefiting from these percutaneous ablation techniques to treat small tumors, either using heat (radiofrequency, microwave) or cold (cryotherapy). These treatments are performed within a dedicated unit consisting of three operating rooms with two interventional scanners and an angiography table. The advent of robotics in interventional radiology will further enhance the safety and precision of these procedures.

Professor Norbert Vey, General Director of IPC, explains

“IPC is a cancer center dedicated to offering increasingly effective treatments to its patients. IPC’s strategy now includes developing minimally invasive interventions to enhance patients’ quality of life and reduce after-effects. By offering minimally invasive tumor ablations, IPC will be able to treat more patients and improve their comfort.”

Partnership

Quantum Surgical and the Paoli-Calmettes Institute have signed a scientific and clinical partnership agreement focusing on clinical studies, with Quantum Surgical acting as the promoter, as well as pioneering topics in robotics.

Dr. Gilles Piana, Head of the Medical Imaging Department at IPC

“Epione® is a unique robotic solution that enables the treatment of tumors in hard-to-reach areas, where only a few experts can intervene. With the robot, these minimally invasive treatments will be standardized, allowing us to provide this curative treatment to a larger number of patients.”

A Significant Milestone for Quantum Surgical

“This new acquisition by the Paoli-Calmettes Institute in Marseille marks a significant milestone for Quantum Surgical and is a recognition of the benefits of Epione®. We are delighted that an increasing number of patients can benefit from our minimally invasive technology, which destroys tumors while improving their comfort,” states Bertin Nahum, President and Co-founder of Quantum Surgical.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”